ECSP066893A - Inhibidores de proteínas de apoptosis (iap) - Google Patents
Inhibidores de proteínas de apoptosis (iap)Info
- Publication number
- ECSP066893A ECSP066893A EC2006006893A ECSP066893A ECSP066893A EC SP066893 A ECSP066893 A EC SP066893A EC 2006006893 A EC2006006893 A EC 2006006893A EC SP066893 A ECSP066893 A EC SP066893A EC SP066893 A ECSP066893 A EC SP066893A
- Authority
- EC
- Ecuador
- Prior art keywords
- iap
- protein inhibitors
- apoptosis protein
- apoptosis
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Novedosos compuestos que inhiben el enlace de la proteína Smac al Inhibidor de Proteínas de Apoptosis (IAP) de la fórmula (I).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56018604P | 2004-04-07 | 2004-04-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP066893A true ECSP066893A (es) | 2006-11-24 |
Family
ID=34962601
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2006006893A ECSP066893A (es) | 2004-04-07 | 2006-09-29 | Inhibidores de proteínas de apoptosis (iap) |
Country Status (32)
Country | Link |
---|---|
US (4) | US7419975B2 (es) |
EP (3) | EP2065368A1 (es) |
JP (3) | JP4691549B2 (es) |
KR (2) | KR100892185B1 (es) |
CN (1) | CN1964970B (es) |
AR (1) | AR048927A1 (es) |
AU (1) | AU2005231956B2 (es) |
BR (1) | BRPI0509721A (es) |
CA (1) | CA2560162C (es) |
CY (1) | CY1113511T1 (es) |
DK (1) | DK2253614T3 (es) |
EC (1) | ECSP066893A (es) |
ES (2) | ES2394441T3 (es) |
HK (1) | HK1100930A1 (es) |
HR (1) | HRP20121023T1 (es) |
IL (1) | IL178104A (es) |
MA (1) | MA28630B1 (es) |
ME (1) | ME02125B (es) |
MY (1) | MY165401A (es) |
NO (1) | NO20065114L (es) |
NZ (1) | NZ549925A (es) |
PE (2) | PE20060166A1 (es) |
PL (1) | PL2253614T3 (es) |
PT (1) | PT2253614E (es) |
RS (1) | RS52545B (es) |
RU (1) | RU2425838C2 (es) |
SG (1) | SG152225A1 (es) |
SI (1) | SI2253614T1 (es) |
TN (1) | TNSN06323A1 (es) |
TW (1) | TWI417092B (es) |
WO (1) | WO2005097791A1 (es) |
ZA (1) | ZA200607696B (es) |
Families Citing this family (140)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2558615C (en) | 2004-03-23 | 2013-10-29 | Genentech, Inc. | Azabicyclo-octane inhibitors of iap |
RS52545B (en) | 2004-04-07 | 2013-04-30 | Novartis Ag | INHIBITORI PROTEIN APOPTOZE (IAP) |
CA2570321C (en) | 2004-07-02 | 2013-10-08 | Genentech, Inc. | Inhibitors of iap |
EP1773766B1 (en) | 2004-07-15 | 2014-04-02 | Tetralogic Pharmaceuticals Corporation | Iap binding compounds |
KR101278732B1 (ko) * | 2004-12-20 | 2013-07-09 | 제넨테크, 인크. | Iap의 피롤리딘 억제제 |
US20080300259A1 (en) * | 2005-02-23 | 2008-12-04 | Hauske James R | Multimediator 5-Ht6 Receptor Antagonists, and Uses Related Thereto |
ES2456671T3 (es) | 2005-02-25 | 2014-04-23 | Tetralogic Pharmaceuticals Corporation | Inhibidores diméricos de IAP |
WO2006107964A2 (en) * | 2005-04-06 | 2006-10-12 | Novartis Ag | Processes to prepare 6-phenethyl-octahydro-pyrrolo [2 , 3-c] pyridine and related compounds |
JP4954983B2 (ja) * | 2005-05-18 | 2012-06-20 | ファーマサイエンス・インコーポレイテッド | Birドメイン結合化合物 |
US20070042428A1 (en) * | 2005-08-09 | 2007-02-22 | Stacy Springs | Treatment of proliferative disorders |
US20100256046A1 (en) * | 2009-04-03 | 2010-10-07 | Tetralogic Pharmaceuticals Corporation | Treatment of proliferative disorders |
KR20080067357A (ko) | 2005-10-25 | 2008-07-18 | 에게라 쎄라퓨틱스 인코포레이티드 | Iap bir 도메인 결합 화합물 |
JP5155184B2 (ja) * | 2005-12-19 | 2013-02-27 | ジェネンテック, インコーポレイテッド | Iapのインヒビター |
JP5227805B2 (ja) | 2005-12-20 | 2013-07-03 | ノバルティス アーゲー | Iap阻害剤とタキサン7の組合せ剤 |
TWI543988B (zh) | 2006-03-16 | 2016-08-01 | 科學製藥股份有限公司 | 結合於細胞凋亡抑制蛋白(iap)之桿狀病毒iap重複序列(bir)區域之化合物 |
US20090099103A1 (en) * | 2006-04-05 | 2009-04-16 | Novartis Ag. | Combinations of therapeutic agents for treating cancer |
EP2606890A1 (en) * | 2006-04-05 | 2013-06-26 | Novartis AG | Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer |
US8168383B2 (en) | 2006-04-14 | 2012-05-01 | Cell Signaling Technology, Inc. | Gene defects and mutant ALK kinase in human solid tumors |
DK2450437T3 (en) | 2006-04-14 | 2017-09-11 | Cell Signaling Technology Inc | Gene defects and mutant ALK kinase in human solid tumors |
CN101535300B (zh) | 2006-05-16 | 2014-05-28 | 埃格拉医疗公司 | Iap bir域结合化合物 |
RU2446170C2 (ru) * | 2006-05-16 | 2012-03-27 | Эгера Терапьютикс Инк. | Соединения, связывающиеся с bir доменом iap |
US8143426B2 (en) * | 2006-07-24 | 2012-03-27 | Tetralogic Pharmaceuticals Corporation | IAP inhibitors |
US20100056495A1 (en) * | 2006-07-24 | 2010-03-04 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
WO2008014240A2 (en) * | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
KR20090041391A (ko) * | 2006-07-24 | 2009-04-28 | 테트랄로직 파마슈티칼스 | 이량체성 iap 길항제 |
US20100144650A1 (en) * | 2006-07-24 | 2010-06-10 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
PE20080951A1 (es) * | 2006-08-02 | 2008-09-11 | Novartis Ag | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS |
MX2009003834A (es) * | 2006-10-12 | 2009-04-22 | Novartis Ag | Derivados de pirrolidina como inhibidores de iap. |
CA2665838A1 (en) * | 2006-10-19 | 2008-05-15 | Novartis Ag | Organic compounds |
KR20090083412A (ko) * | 2006-11-28 | 2009-08-03 | 노파르티스 아게 | 급성 골수성 백혈병의 치료를 위한 iap 억제제의 용도 |
MX2009005621A (es) * | 2006-11-28 | 2009-06-12 | Novartis Ag | Combinacion de inhibidores de iap e inhibidores de flt3. |
NZ577150A (en) * | 2006-12-19 | 2012-04-27 | Genentech Inc | Imidazopyridine inhibitors of iap |
WO2008109057A1 (en) * | 2007-03-02 | 2008-09-12 | Dana-Farber Cancer Institute, Inc. | Organic compounds and their uses |
MX2009010667A (es) | 2007-04-12 | 2010-02-24 | Joyant Pharmaceuticals Inc | Dimeros y trimeros mimeticos de smac utiles como agentes anti-cancer. |
BRPI0809867A2 (pt) * | 2007-04-30 | 2014-09-30 | Genentech Inc | Composto, método de indução da apoptose em uma célula, método de sensibilização de uma célula para um sinal apoptótico, método para inibir a ligação de uma proteína iap a uma proteína caspase e métodos |
WO2008137930A1 (en) * | 2007-05-07 | 2008-11-13 | Tetralogic Pharmaceuticals Corp. | TNFα GENE EXPRESSION AS A BIOMARKER OF SENSITIVITY TO ANTAGONISTS OF INHIBITOR OF APOPTOSIS PROTEINS |
WO2008144925A1 (en) * | 2007-05-30 | 2008-12-04 | Aegera Therapeutics Inc. | Iap bir domain binding compounds |
CN101970457A (zh) * | 2008-01-11 | 2011-02-09 | 健泰科生物技术公司 | Iap抑制剂 |
KR20100119768A (ko) * | 2008-01-24 | 2010-11-10 | 테트랄로직 파마슈티칼스 코포레이션 | 아이에이피 억제제 |
WO2009136290A1 (en) * | 2008-05-05 | 2009-11-12 | Aegera Therapeutics, Inc. | Functionalized pyrrolidines and use thereof as iap inhibitors |
US9750729B2 (en) * | 2008-05-16 | 2017-09-05 | Dana-Farber Cancer Institute, Inc. | Immunomodulation by IAP inhibitors |
AU2009261919A1 (en) * | 2008-06-27 | 2009-12-30 | Pharmascience Inc. | Bridged secondary amines and use thereof as IAP BIR domain binding compounds |
WO2010017035A2 (en) | 2008-08-02 | 2010-02-11 | Genentech, Inc. | Inhibitors of iap |
CN102124004A (zh) * | 2008-08-16 | 2011-07-13 | 健泰科生物技术公司 | Iap的氮杂吲哚抑制剂 |
EP2328412A4 (en) * | 2008-09-17 | 2012-03-14 | Tetralogic Pharm Corp | IPA INHIBITORS |
US8841067B2 (en) | 2009-01-09 | 2014-09-23 | Dana-Farber Cancer Institute, Inc. | NOL3 is a predictor of patient outcome |
AU2010254056A1 (en) * | 2009-05-28 | 2011-12-15 | Tetralogic Pharmaceuticals Corp. | IAP inhibitors |
EP2434889B1 (en) * | 2009-05-28 | 2016-03-09 | Tetralogic Birinapant UK Ltd | Iap inhibitors |
CN101928326B (zh) * | 2009-06-24 | 2015-07-08 | 中国人民解放军军事医学科学院毒物药物研究所 | 取代的氨酰基五元杂环烷类化合物及其用途 |
US8283372B2 (en) | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
TW201109335A (en) * | 2009-08-04 | 2011-03-16 | Takeda Pharmaceutical | Heterocyclic compounds |
MX351274B (es) | 2009-08-12 | 2017-10-06 | Novartis Ag | Formulaciones orales sólidas y formas cristalinas de un inhibidor de la proteína de apoptosis. |
EP2478358A1 (en) | 2009-09-18 | 2012-07-25 | Novartis AG | Biomarkers for iap inhibitor compounds |
US8551955B2 (en) | 2009-10-28 | 2013-10-08 | Joyant Pharmaceuticals, Inc. | Dimeric Smac mimetics |
SG182724A1 (en) | 2010-02-12 | 2012-08-30 | Pharmascience Inc | Iap bir domain binding compounds |
UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
EP2560659A4 (en) * | 2010-04-19 | 2013-05-01 | Stanford Res Inst Int | COMPOSITIONS AND METHODS FOR TREATING MULTIPLE MYELOMA |
WO2012052758A1 (en) | 2010-10-22 | 2012-04-26 | Astrazeneca Ab | Response biomarkers for iap antagonists in human cancers |
GB201106817D0 (en) | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compound |
AU2012315986A1 (en) | 2011-09-30 | 2014-04-17 | Srinivas Chunduru | Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer) |
GB201121132D0 (en) * | 2011-12-08 | 2012-01-18 | Dow Corning | Modifying polymeric materials by amines |
GB201121124D0 (en) | 2011-12-08 | 2012-01-18 | Dow Corning | Hydrolysable silanes |
GB201121122D0 (en) | 2011-12-08 | 2012-01-18 | Dow Corning | Hydrolysable silanes and elastomer compositions containing them |
GB201121133D0 (en) * | 2011-12-08 | 2012-01-18 | Dow Corning | Hydrolysable silanes |
GB201121128D0 (en) | 2011-12-08 | 2012-01-18 | Dow Corning | Treatment of filler with silane |
US20130196927A1 (en) * | 2012-01-27 | 2013-08-01 | Christopher BENETATOS | Smac Mimetic Therapy |
JP6513019B2 (ja) | 2012-05-04 | 2019-05-15 | ノバルティス アーゲー | Iapインヒビター治療のためのバイオマーカー |
KR20140011773A (ko) * | 2012-07-19 | 2014-01-29 | 한미약품 주식회사 | 이중 저해 활성을 갖는 헤테로고리 유도체 |
US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
US9498543B2 (en) | 2013-03-15 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
US20140303090A1 (en) * | 2013-04-08 | 2014-10-09 | Tetralogic Pharmaceuticals Corporation | Smac Mimetic Therapy |
CN111481669A (zh) | 2013-06-25 | 2020-08-04 | 沃尔特和伊利莎豪医学研究所 | 治疗细胞内感染的方法 |
GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
US9249151B2 (en) * | 2013-08-23 | 2016-02-02 | Boehringer Ingelheim International Gmbh | Bis-amido pyridines |
US9278978B2 (en) * | 2013-08-23 | 2016-03-08 | Boehringer Ingelheim International Gmbh | 6-Alkynyl Pyridine |
EP3686200A3 (en) | 2013-12-20 | 2020-09-09 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
US10441654B2 (en) | 2014-01-24 | 2019-10-15 | Children's Hospital Of Eastern Ontario Research Institute Inc. | SMC combination therapy for the treatment of cancer |
WO2015187998A2 (en) | 2014-06-04 | 2015-12-10 | Sanford-Burnham Medical Research Institute | Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy |
US10786578B2 (en) | 2014-08-05 | 2020-09-29 | Novartis Ag | CKIT antibody drug conjugates |
US10238748B2 (en) | 2014-08-12 | 2019-03-26 | Novartis Ag | Anti-CDH6 antibody drug conjugates |
WO2016079527A1 (en) | 2014-11-19 | 2016-05-26 | Tetralogic Birinapant Uk Ltd | Combination therapy |
WO2016097773A1 (en) | 2014-12-19 | 2016-06-23 | Children's Cancer Institute | Therapeutic iap antagonists for treating proliferative disorders |
JP6817962B2 (ja) | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
US20170327469A1 (en) | 2015-01-20 | 2017-11-16 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
CN104592214A (zh) * | 2015-02-13 | 2015-05-06 | 佛山市赛维斯医药科技有限公司 | 含葡萄糖酰胺吡啶和烷氧吡嗪结构的化合物及用途 |
EP3302482A4 (en) | 2015-06-05 | 2018-12-19 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
EP3310813A1 (en) | 2015-06-17 | 2018-04-25 | Novartis AG | Antibody drug conjugates |
US20170037004A1 (en) * | 2015-07-13 | 2017-02-09 | Arvinas, Inc. | Alanine-based modulators of proteolysis and associated methods of use |
US10772962B2 (en) | 2015-08-19 | 2020-09-15 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
CN105585583B (zh) * | 2016-01-20 | 2018-04-13 | 广东工业大学 | 一种非肽类凋亡抑制蛋白拮抗剂及其合成方法与应用 |
CN105566447B (zh) * | 2016-01-20 | 2019-09-20 | 广东工业大学 | 一种凋亡抑制蛋白的类肽拮抗剂及其合成方法与应用 |
CN106188098B (zh) * | 2016-07-06 | 2017-11-03 | 广东工业大学 | 一种杂化抗癌药物及其制备方法与应用 |
BR112019003897A2 (pt) * | 2016-08-29 | 2019-05-21 | The Regents Of The University Of Michigan | aminopirimidinas como inibidores de alk |
JP6899993B2 (ja) * | 2016-10-04 | 2021-07-07 | 国立医薬品食品衛生研究所長 | 複素環化合物 |
JP7286539B2 (ja) | 2016-11-01 | 2023-06-05 | アルビナス・オペレーションズ・インコーポレイテッド | タウタンパク質標的化protac、および関連使用方法 |
AU2017366693B2 (en) | 2016-12-01 | 2021-04-01 | Arvinas Operations, Inc. | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders |
CN117510491A (zh) | 2016-12-23 | 2024-02-06 | 阿尔维纳斯运营股份有限公司 | 用于迅速加速性纤维肉瘤多肽的靶向降解的化合物和方法 |
US10806737B2 (en) | 2016-12-23 | 2020-10-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
KR20190101406A (ko) | 2016-12-23 | 2019-08-30 | 아비나스 오퍼레이션스, 인코포레이티드 | Egfr 단백질분해 표적화 키메라 분자 및 관련 사용 방법 |
US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
MX2019008934A (es) | 2017-01-26 | 2019-11-05 | Arvinas Operations Inc | Moduladores de la proteolisis del receptor de estrogeno y métodos asociados de uso,. |
JOP20190187A1 (ar) | 2017-02-03 | 2019-08-01 | Novartis Ag | مترافقات عقار جسم مضاد لـ ccr7 |
US11179413B2 (en) | 2017-03-06 | 2021-11-23 | Novartis Ag | Methods of treatment of cancer with reduced UBB expression |
WO2018185618A1 (en) | 2017-04-03 | 2018-10-11 | Novartis Ag | Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment |
AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
JP2020520665A (ja) | 2017-05-24 | 2020-07-16 | ノバルティス アーゲー | 抗体−サイトカイングラフト化タンパク質及び癌の治療における使用方法 |
WO2018215938A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use |
WO2018215937A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer |
US11358950B2 (en) * | 2017-11-13 | 2022-06-14 | Chia Tai Tiangqing Pharmaceutical Group Co., Ltd. | SMAC mimetics used as IAP inhibitors and use thereof |
WO2019099926A1 (en) | 2017-11-17 | 2019-05-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
WO2019177902A1 (en) | 2018-03-10 | 2019-09-19 | Yale University | Modulators of btk proteolysis and methods of use |
CA3095494C (en) | 2018-04-04 | 2023-11-07 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
PE20210405A1 (es) | 2018-07-10 | 2021-03-02 | Novartis Ag | Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de enfermedades dependientes de la proteina con dedos de zinc 2 de la familia ikaros (ikzf2) |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
WO2020023851A1 (en) | 2018-07-26 | 2020-01-30 | Yale University | Bifunctional substitued pyrimidines as modulators of fak proteolyse |
EP3841100A1 (en) | 2018-08-20 | 2021-06-30 | Arvinas Operations, Inc. | Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases |
AU2019335516B2 (en) | 2018-09-07 | 2022-06-16 | Arvinas Operations, Inc. | Polycyclic compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
WO2020089811A1 (en) | 2018-10-31 | 2020-05-07 | Novartis Ag | Dc-sign antibody drug conjugates |
KR20210106437A (ko) | 2018-12-20 | 2021-08-30 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물 |
PE20211296A1 (es) | 2018-12-21 | 2021-07-20 | Novartis Ag | Anticuerpos anti-pmel17 y conjugados de los mismos |
EP3924054A1 (en) | 2019-02-15 | 2021-12-22 | Novartis AG | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
CA3123519A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
US11912699B2 (en) | 2019-07-17 | 2024-02-27 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated |
CN114514032A (zh) | 2019-08-02 | 2022-05-17 | 兰提欧派普有限公司 | 用于治疗癌症的血管紧张素2型(at2)受体激动剂 |
US20230057071A1 (en) | 2019-12-20 | 2023-02-23 | Novartis Ag | Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome |
CN114980883A (zh) | 2020-01-20 | 2022-08-30 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的表皮生长因子受体酪氨酸激酶抑制剂 |
WO2021220178A1 (en) | 2020-04-29 | 2021-11-04 | Cominnex Zrt. | Iap antagonists and their therapeutic applications |
US20230181756A1 (en) | 2020-04-30 | 2023-06-15 | Novartis Ag | Ccr7 antibody drug conjugates for treating cancer |
CN116096862A (zh) | 2020-06-11 | 2023-05-09 | 诺华股份有限公司 | Zbtb32抑制剂及其用途 |
CA3182346A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
EP4188549A1 (en) | 2020-08-03 | 2023-06-07 | Novartis AG | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
JP2024517409A (ja) | 2021-04-16 | 2024-04-22 | ノバルティス アーゲー | 抗体薬物結合体及びその作成方法 |
AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
WO2024023666A1 (en) | 2022-07-26 | 2024-02-01 | Novartis Ag | Crystalline forms of an akr1c3 dependent kars inhibitor |
WO2024054591A1 (en) | 2022-09-07 | 2024-03-14 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
DE2714880A1 (de) * | 1977-04-02 | 1978-10-26 | Hoechst Ag | Cephemderivate und verfahren zu ihrer herstellung |
DE3372965D1 (en) | 1982-07-23 | 1987-09-17 | Ici Plc | Amide derivatives |
JPS59141547A (ja) | 1983-02-01 | 1984-08-14 | Eisai Co Ltd | 鎮痛作用を有する新規ペプタイドおよび製法 |
GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
FR2575753B1 (fr) * | 1985-01-07 | 1987-02-20 | Adir | Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
DK167813B1 (da) * | 1989-12-07 | 1993-12-20 | Carlbiotech Ltd As | Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
TW225528B (es) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
US5559209A (en) * | 1993-02-18 | 1996-09-24 | The General Hospital Corporation | Regulator regions of G proteins |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
EP2295415A1 (en) | 1995-03-30 | 2011-03-16 | OSI Pharmaceuticals, Inc. | Quinazoline derivatives |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
HUP9900330A3 (en) | 1995-07-06 | 2001-08-28 | Novartis Ag | Pyrrolopyrimidines and processes for the preparation thereof |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
ES2174250T5 (es) | 1996-04-12 | 2010-04-21 | Warner-Lambert Company Llc | Inhibidores irreversibles de tirosina quinasas. |
WO1997049688A1 (en) | 1996-06-24 | 1997-12-31 | Pfizer Inc. | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases |
WO1998008849A1 (de) | 1996-08-30 | 1998-03-05 | Novartis Aktiengesellschaft | Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens |
ATE247724T1 (de) | 1996-09-06 | 2003-09-15 | Obducat Ab | Verfahren für das anisotrope ätzen von strukturen in leitende materialien |
EP0954315A2 (en) | 1996-09-13 | 1999-11-10 | Sugen, Inc. | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
EP1367057B1 (de) | 1996-11-18 | 2008-09-17 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Epothilone E und F |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
ATE307123T1 (de) | 1998-02-25 | 2005-11-15 | Sloan Kettering Inst Cancer | Synthese von epothilonen, ihren zwischenprodukten und analogen verbindungen |
US6472172B1 (en) * | 1998-07-31 | 2002-10-29 | Schering Aktiengesellschaft | DNA encoding a novel human inhibitor-of-apoptosis protein |
CA2339961C (en) | 1998-08-11 | 2009-01-20 | Novartis Ag | Isoquinoline derivatives with angiogenesis inhibiting activity |
CN100381566C (zh) | 1998-11-20 | 2008-04-16 | 科森生物科学公司 | 产生环氧噻酮及其衍生物的重组方法和材料 |
PE20020058A1 (es) * | 2000-05-23 | 2002-01-31 | Vertex Pharma | Derivados de piperidina tetrahidroquinolina, tetrahidroisoquinolina como inhibidores de caspasas |
US6608026B1 (en) * | 2000-08-23 | 2003-08-19 | Board Of Regents, The University Of Texas System | Apoptotic compounds |
PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
US20020160975A1 (en) * | 2001-02-08 | 2002-10-31 | Thomas Jefferson University | Conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO for mediating apoptosis |
AR035885A1 (es) | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
US20030157522A1 (en) * | 2001-11-09 | 2003-08-21 | Alain Boudreault | Methods and reagents for peptide-BIR interaction screens |
EP1519918A1 (en) * | 2002-07-02 | 2005-04-06 | Novartis AG | Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap) |
EP1578777B1 (en) * | 2002-07-15 | 2008-11-26 | The Trustees of Princeton University | Iap binding compounds |
US20040171554A1 (en) * | 2003-02-07 | 2004-09-02 | Genentech, Inc. | Compositions and methods for enhancing apoptosis |
US7067274B2 (en) * | 2003-11-13 | 2006-06-27 | Genentech, Inc. | Compositions and methods for the screening pro-apoptotic compounds |
CA2553871A1 (en) | 2004-01-16 | 2005-08-04 | The Regents Of The University Of Michigan | Smac peptidomimetics and the uses thereof |
CN1926118A (zh) * | 2004-03-01 | 2007-03-07 | 德克萨斯大学董事会 | 二聚的小分子细胞凋亡增强剂 |
RS52545B (en) * | 2004-04-07 | 2013-04-30 | Novartis Ag | INHIBITORI PROTEIN APOPTOZE (IAP) |
CA2570321C (en) | 2004-07-02 | 2013-10-08 | Genentech, Inc. | Inhibitors of iap |
KR101278732B1 (ko) | 2004-12-20 | 2013-07-09 | 제넨테크, 인크. | Iap의 피롤리딘 억제제 |
PE20080951A1 (es) | 2006-08-02 | 2008-09-11 | Novartis Ag | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS |
-
2005
- 2005-04-06 RS RS20120557A patent/RS52545B/en unknown
- 2005-04-06 BR BRPI0509721-5A patent/BRPI0509721A/pt not_active Application Discontinuation
- 2005-04-06 ME MEP-2012-557A patent/ME02125B/me unknown
- 2005-04-06 SG SG200902372-2A patent/SG152225A1/en unknown
- 2005-04-06 PL PL10172398T patent/PL2253614T3/pl unknown
- 2005-04-06 EP EP09153639A patent/EP2065368A1/en not_active Withdrawn
- 2005-04-06 DK DK10172398.9T patent/DK2253614T3/da active
- 2005-04-06 PE PE2005000384A patent/PE20060166A1/es active IP Right Grant
- 2005-04-06 US US11/099,941 patent/US7419975B2/en active Active
- 2005-04-06 ES ES05716547T patent/ES2394441T3/es active Active
- 2005-04-06 EP EP05716547A patent/EP1735307B1/en active Active
- 2005-04-06 NZ NZ549925A patent/NZ549925A/en not_active IP Right Cessation
- 2005-04-06 KR KR1020067023240A patent/KR100892185B1/ko active IP Right Grant
- 2005-04-06 RU RU2006139010/04A patent/RU2425838C2/ru active
- 2005-04-06 WO PCT/EP2005/003619 patent/WO2005097791A1/en active Application Filing
- 2005-04-06 ES ES10172398T patent/ES2396195T3/es active Active
- 2005-04-06 TW TW094110874A patent/TWI417092B/zh not_active IP Right Cessation
- 2005-04-06 PE PE2009001297A patent/PE20110102A1/es active IP Right Grant
- 2005-04-06 CN CN2005800186137A patent/CN1964970B/zh not_active Expired - Fee Related
- 2005-04-06 AR ARP050101365A patent/AR048927A1/es not_active Application Discontinuation
- 2005-04-06 AU AU2005231956A patent/AU2005231956B2/en not_active Ceased
- 2005-04-06 MY MYPI20051543A patent/MY165401A/en unknown
- 2005-04-06 JP JP2007506718A patent/JP4691549B2/ja not_active Expired - Fee Related
- 2005-04-06 PT PT101723989T patent/PT2253614E/pt unknown
- 2005-04-06 US US10/594,413 patent/US20080242658A1/en not_active Abandoned
- 2005-04-06 EP EP10172398A patent/EP2253614B1/en active Active
- 2005-04-06 CA CA2560162A patent/CA2560162C/en active Active
- 2005-04-06 KR KR1020087021449A patent/KR20080083220A/ko not_active Application Discontinuation
- 2005-04-06 SI SI200531639T patent/SI2253614T1/sl unknown
-
2006
- 2006-09-14 ZA ZA200607696A patent/ZA200607696B/en unknown
- 2006-09-14 IL IL178104A patent/IL178104A/en active IP Right Grant
- 2006-09-29 EC EC2006006893A patent/ECSP066893A/es unknown
- 2006-10-06 TN TNP2006000323A patent/TNSN06323A1/en unknown
- 2006-10-30 MA MA29422A patent/MA28630B1/fr unknown
- 2006-11-06 NO NO20065114A patent/NO20065114L/no not_active Application Discontinuation
-
2007
- 2007-06-06 HK HK07106025.9A patent/HK1100930A1/xx not_active IP Right Cessation
-
2010
- 2010-04-27 JP JP2010102494A patent/JP2010215635A/ja not_active Withdrawn
-
2011
- 2011-07-08 US US13/178,946 patent/US8207183B2/en active Active
-
2012
- 2012-04-26 US US13/456,274 patent/US8338440B2/en active Active
- 2012-12-12 HR HRP20121023TT patent/HRP20121023T1/hr unknown
- 2012-12-13 JP JP2012272668A patent/JP2013049733A/ja active Pending
- 2012-12-19 CY CY20121101238T patent/CY1113511T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP066893A (es) | Inhibidores de proteínas de apoptosis (iap) | |
MX2009003834A (es) | Derivados de pirrolidina como inhibidores de iap. | |
CY1109911T1 (el) | Πυρρολοβενζοδιαζεπινες | |
WO2006133147A3 (en) | Organic compounds | |
BRPI0606379A2 (pt) | triazolftalazinas | |
CU20090017A7 (es) | Peptidomimeticos de smac utiles como inhibidores de proteinas de apoptosis (iap) | |
NO20081636L (no) | FAP - inhibitorer | |
CR20120421A (es) | Compuestos de aminohetetoarilo o sustituidos con pirazol como inhibidores de proteina quinasa | |
ATE400567T1 (de) | Kinaseinhibitoren | |
MX2008000017A (es) | Derivados de isoquinolina como inhibidores de rho-cinasa. | |
CR9604A (es) | Derivados de ciclohexilaminisoquinolona en calidad de inhibidores de rho-quinasa | |
CR9244A (es) | AMINO-IMIDAZOLONAS PARA LA INHIBICION DE ß-SECRETASA | |
ATE542798T1 (de) | Organische verbindungen | |
NO20083492L (no) | 11-Beta HSD1 inhibitorer | |
ATE471324T1 (de) | Triazolophthalazine | |
UY29612A1 (es) | Compuestos quimicos ii | |
WO2006052568A3 (en) | Tgf-beta inhibitors | |
EA200801145A1 (ru) | Спироциклические производные хиназолина в качестве ингибиторов pde7 | |
EA200801413A1 (ru) | Гетероциклические сетр ингибиторы | |
DOP2005000010A (es) | Inhibidores de quinasa | |
ATE510821T1 (de) | Sulfonylpyrrole als histondeacetylaseinhibitoren | |
ATE417849T1 (de) | Pyrazoloä4,3-düpyrimidine | |
NO20081207L (no) | Isoquinolines as IGF-1R inhibitors | |
ATE430148T1 (de) | Neue pyrrolodihydroisochinoline als pde10- inhibitoren | |
EA200700254A1 (ru) | Димерные производные пипередина |